Clinical trial NCT04085991: Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer
Official title: Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Prostate Cancer
Prostate Adenocarcinoma
Prostatic Neoplasms
Metastatic Prostate Cancer
Metastatic Prostatic Adenocarcinoma
Metastatic Prostate Carcinoma in the Soft Tissue
Keywords: Radioligand therapy
PSMA
PSMA therapy
1095
Lead sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Sponsor class: OTHER
First posted: 2019-09-11
Enrollment: 11
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Single-arm, open-label, phase II trial in 200 competent adult male patients with Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-3 and progressive metastatic prostate cancer, failing, failed, refused, not eligible for or no access to further approved lines of therapy. Patients will undergo sequential FDG positron emission tomography (PET) and 18F-DCFPyL PET to assess FDG/DCFPyL concordance fraction. Patients with DCFPyL/FDG concordance of 50% or greater will be treated with 131I-PSMA-1095 radioligand therapy (RLT). Best post-treatment serum prostate specific antigen response will be compared to concordance fraction.


Eligibility criteria: Inclusion Criteria:

* Male
* Age 18 years or older
* Documented metastatic adenocarcinoma of the prostate
* Under active medical oncology care
* ECOG performance status 0 - 3, inclusive
* Able to understand and provide written informed consent
* Able to tolerate the physical requirements of two PET/CT scans including lying for up to 30 minutes
* Progressive disease on any of: bone scan, CT, MRI or serum PSA as judged by the investigator
* Serum prostate specific antigen ≥ 1 ng/ml at baseline or CT/MRI soft-tissue measurable disease as per RECIST v1.1
* Failed, failing, refused, no access to or not eligible for any approved prostate cancer therapies including but not limited to: ADT, NAAD (e.g., abiraterone, enzalutamide, darolutamide or apalutamide), docetaxel, cabazitaxel, radium-223 and oligometastatic RTX
* Life expectancy of at least 3 months as judged by the investigator

Exclusion Criteria:

* Medically unstable (e.g. acute cardiac or respiratory distress or hypotensive)
* Exceeding the weight limit of the PET/CT bed (approximately 400 lbs.) or who cannot fit through the PET/CT bore (approximately 70 cm diameter)
* Unmanageable claustrophobia
* Prior failure of PSMA RLT
* Prior hemi-body irradiation
* Impaired organ function as evidenced by any of the following laboratory values:

  * Absolute neutrophil count \< 1.5 x109/L
  * Platelet count \< 75 x109/L
  * Hemoglobin \< 85 g/L
  * Albumin \< 2.5 g/dL (25 g/L)
  * Total bilirubin \> 2 x ULN (unless in instances of Gilbert's disease)
  * AST or ALT \> 2.5 x ULN (or \> 5.0 x ULN in the presence of liver metastases)

Primary outcomes:
measure: Serum prostate specific antigen (PSA)
timeFrame: 3 months post last dose of RLT
Secondary outcomes:
measure: Adverse events
timeFrame: 3 months post last dose of RLT
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Stephan Probst
state: Quebec
Study officials:
affiliation: Jewish General Hospital
name: Stephan Probst, MD
role: PRINCIPAL_INVESTIGATOR
References: